Lafutidine
- Level
- Commodity
- Parent
- 51171900
- Below
- 0
- Links · KBLI
- 9
Definition
UNSPSC 51171946This classification denotes a histamine-2 receptor antagonist with the molecular formula C22H29N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49S4O7ADLC, chemically known as acetamide, 2-((2-furanylmethyl)sulfinyl)-n-(4-((4-(1-piperidinylmethyl)-2-pyridinyl)oxy)-2-butenyl)-, (z)- but generally known as lafutidine, which bears US NIH Compound Identifier 5282136. European Medicines Agency schedules Lafutidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08388MIG. The term LAFUTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules lafutidine in its Anatomical Therapeutic Chemical (ATC) Classification. LAFUTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lafutidine under HS 29349990 and SITC 51579. As of Q4 2014, LAFUTIDINE remains the US FDA Preferred Term for this commodity. Lafutidine bears US NLM identifiers UMLS ID C0172827 and NCI Concept Code C79117. SMILES: S(=O)(CC1OCCC1)CC(=O)NC/C=C\COC1NCCC(CN2CCCCC2)C1.
Same parent
Under 51171900 · 73Activities that produce or sell this
KBLI · 9Inherited from family 51170000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.